<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003205</url>
  </required_header>
  <id_info>
    <org_study_id>97-0751.cc</org_study_id>
    <secondary_id>UCHSC-97751</secondary_id>
    <secondary_id>NCI-T97-0063</secondary_id>
    <nct_id>NCT00003205</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 in Treating Patients With Stage IV Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with&#xD;
      stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical response of patients with stage IV breast cancer to bryostatin 1.&#xD;
&#xD;
        -  Determine the efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Estimate the pharmacokinetic parameters of bryostatin 1 when given as 24 hour infusion.&#xD;
&#xD;
        -  Determine the ability of this regimen to regulate lymphocyte function in these patients.&#xD;
&#xD;
        -  Determine the effect of this regimen on platelet function and protein kinase C activity&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive bryostatin 1 IV over 24 hours. Treatment continues weekly in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 4-8 weeks for tumor response.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Unequivocal diagnosis of metastatic breast cancer&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No uncontrolled CNS metastases&#xD;
&#xD;
          -  No disease that is evaluable only, including blastic bone disease, malignant ascites,&#xD;
             and malignant pleural effusion&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 18 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
          -  PT and PTT within normal limits&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.2 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 3 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infections requiring antibiotics&#xD;
&#xD;
          -  No viral hepatitis allowed&#xD;
&#xD;
          -  Seronegative for hepatitis B or C&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months following&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  2 prior chemotherapy regimens for metastatic disease allowed as adjuvant therapy or&#xD;
             for advanced disease (may include high dose chemotherapy with stem cell support)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosourea or mitomycin therapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  2 prior hormonal therapy regimens for metastatic disease as adjuvant therapy or for&#xD;
             advanced diseases allowed&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy (at least 4 weeks in case of disease&#xD;
             progression while receiving hormonal therapy after initial response)&#xD;
&#xD;
          -  No concurrent hormonal therapy except oral contraceptives&#xD;
&#xD;
          -  No concurrent use of steroids except for management of severe or life- threatening&#xD;
             toxic effects arising from bryostatin 1&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent use of drugs known to interfere with platelet function, such as aspirin&#xD;
             or NSAIDs (including ibuprofen)&#xD;
&#xD;
          -  No concurrent use of anticoagulants&#xD;
&#xD;
          -  At least 2 weeks since prior use of aspirin&#xD;
&#xD;
          -  At least 2 days since prior use of NSAIDS&#xD;
&#xD;
          -  Concurrent use of acetaminophen to control pain is allowed&#xD;
&#xD;
          -  If acetaminophen inadequate for pain control, concurrent use of oral narcotics such as&#xD;
             codeine or oxycodone is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Kraft, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2003</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

